Introduction to IBD Animal Models

Chronic enteritis is a chronic, relapsing condition characterized by mucosal edema, congestion, ulceration, and bleeding in the intestinal tract. Its hallmark symptoms include diarrhea, constipation, abdominal pain, bloating, nausea, and decreased appetite. It is one of the more common disorders of the gastrointestinal system and can occur at any age.

Advantages of the IBD Animal Model Platform Services at Aniphe BioLab

This platform boasts a comprehensive animal model system for inflammatory bowel disease (IBD) and robust technical expertise, enabling mechanistic studies, drug screening, and preclinical efficacy evaluation.

	The symptoms are consistent with clinical findings. The condition stably recurs with typical symptoms such as intestinal mucosal erosion, ulcers, inflammatory infiltration, diarrhea, hematochezia, and weight loss.
	The model exhibits excellent uniformity. High modeling success rate, minimal inter-individual variability, and strong experimental reproducibility ensure data accuracy.
	Standardized end-to-end control Animals are housed under SPF‑grade conditions, with real-time monitoring of their health status, standardized experimental procedures, and fully traceable data.
	Comprehensive testing items Supports multi-dimensional detection and analysis of intestinal pathology, inflammatory factors, gut microbiota, intestinal barrier function, and more.
	One-stop, end-to-end service We offer an integrated service encompassing model creation, animal husbandry and observation, sample collection, and biomarker analysis, efficiently supporting scientific research.

Modeling cycle	12–16 weeks
Laboratory animals	Mice and rats, IL-10 knockout mice (spontaneous colitis model mice)
Positive drug	Commonly used positive control drugs such as mesalazine, sulfasalazine, and dexamethasone can alleviate intestinal inflammation and promote mucosal repair.
Application areas	It is widely applied in areas such as research on the mechanisms of intestinal inflammation, screening of anti-inflammatory and immunomodulatory drugs, evaluation of intestinal mucosal barrier function, investigation of host–microbiota interactions, and the development of biologics and novel therapeutic strategies, thereby providing an essential experimental platform for basic research on inflammatory bowel disease and related intestinal disorders, as well as for new drug discovery.

Construction of IBD Animal Models

DSS‑induced acute and chronic ulcerative colitis models: Models are established by allowing animals to freely drink DSS solutions of varying concentrations. Short‑term administration induces acute colitis, while prolonged administration combined with alternating periods of normal water intake can establish chronic relapsing colitis. The drug disrupts the intestinal mucosal barrier, leading to intestinal inflammation, erosions, and ulcers.